Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Faricimab to see if it helps improve vision in adults with certain eye conditions, including Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO). The main goals are to find out if Faricimab can enhance the best-corrected vision of participants and to monitor any health issues that may arise from the treatment. Participants will receive an injection of Faricimab every month for three months and will need to visit the clinic every two weeks for checkups.

To be eligible for this trial, participants must be Chinese adults aged 18 or older who have been diagnosed with AMD, DME, or RVO using specific eye tests. They should have already decided to use Faricimab for their treatment before joining the study and must have signed a consent form. It's important to note that individuals with active eye infections or inflammation, those who have received other anti-VEGF therapies after starting Faricimab, or those currently involved in another clinical trial cannot participate. This study offers a chance to access a new treatment while contributing to our understanding of its effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Chinese patients aged 18 years or older and of any gender;
• • 2. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;
• • 3. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;
• • 4. Patients who have received at least one treatment with faricimab during the course of the study;
• • 5. have signed an informed consent form.
• Exclusion Criteria:
• • 1. Active ocular inflammation or suspected active ocular infection in either eye;
• • 2. Receipt of any other anti-VEGF therapy after faricimab;
• • 3. Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection;
• • 4. Currently participating in any other clinical trial.